Clinical Trial Update: A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors and gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DHP107 (paclitaxel)

Snippet

Sponsor: Daehwa Pharmaceutical Co., Ltd. | Conditions: Solid Tumor, Stage IV Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED